Introduction
Oncolytic viruses, which selectively infect or replicate in cancer cells while sparing normal cells, have been explored as alternative cancer therapies in both preclinical and clinical trials. Some of these viruses are naturally occurring wild types, such as Newcastle disease virus, 1 or attenuated strains, such as reovirus 2 and vesicular stomatitis virus. 3 Others are genetically modified to mediate oncolytic effects such as herpes simplex virus (HSV), adenovirus, poxvirus and measles virus. [4] [5] [6] Mutants based on HSV type-1 (HSV-1) have been among the most extensively studied oncolytic viruses and have great potential as anticancer agents because of the following characteristics: (1) it can infect and replicate in a variety of cell types (including tumor cells of human and rodent origins); (2) it is cytolytic by nature (i.e., during its productive infection cycle it can destroy and lyse the infected cells); (3) the wellcharacterized 152-kb genome contains many non-essential genes that, in theory, can be replaced with multiple therapeutic genes (up to 30 kb in size); (4) antiherpetic drugs (e.g., acyclovir) are available to abort unfavorable viral replication and (5) the virus remains as an episome within the infected cell which precludes insertional mutagenesis. 7 HSV-1 double-mutants such as G207 8 and MGH1, 9 which have deletions in both copies of the g 1 34.5 gene and an insertional mutation in the U L 39 gene (encoding ribonucleotide reductase (RR), ICP6), has shown oncolytic effects as well as potent immunizing effects without compromising safety or specificity. [8] [9] [10] [11] [12] [13] Such mutants thus provide optimal templates to produce novel oncolytic HSV vectors for cancer gene therapy applications. However, engineering a new HSV mutant using conventional methods (based on homologous recombination in mammalian cells) is laborious and time-consuming. In order to overcome this problem, we have developed a novel BAC-based method of generating oncolytic HSV vectors (designated as 'HSVQuik system') in which the BAC backbone can be efficiently exchanged with transgene cassettes of interest through two sequential, site-specific recombinations. Taking advantage of the novel methodology, we constructed a series of oncolytic HSV vectors that express firefly luciferase under the control of various viral promoters to monitor transgene expression profiles during the course of viral replication. We then constructed a series of oncolytic HSV vectors expressing immunomodulators and evaluated their anticancer efficacies using two syngeneic mouse brain tumor models.
Results

Cloning of MGH1 genome into a BAC vector
MGH1
9 is a double-mutant oncolytic HSV-1 (F strain) that was generated by inserting the Escherichia coli lacZ gene into the U L 39 (also known as ICP6) locus of the g 1 34.5-deletion mutant R3616. 14 The strategy for cloning the MGH1 genome into a BAC vector is summarized in Figure 1a . First, we constructed a U L 39-targeting BAC plasmid, pRBAC-D6GpA-FL. This construct possesses two homology arms that can recombine with the viral genome upstream and downstream of the lacZ insertion within the U L 39 locus. We also added several features to this plasmid, including (1) a set of two recombination sequences: an FRT site upstream and a loxP site downstream, flanking the BAC backbone to facilitate insertion of transgene cassettes and later removal of procaryotic plasmid sequences from the vector genome; (2) the EGFP coding sequence, inserted in-frame downstream of the truncated ICP6 coding sequence, and a phosphoglycerate kinase (PGK) polyA sequence to facilitate visualization of infected cells and (3) an RFP (DsRed1) expression cassette in the middle of the BAC backbone to monitor the presence of the BAC sequences in the vector genome. The linearized pRBAC-D6GpA-FL DNA was co-transfected with MGH1 virion DNA into Vero cells and the progeny viruses were harvested 3 days after transfection. Two independent clones of GFP-and RFP-positive recombinant viruses were isolated and plaque purified. In order to isolate circular BAC DNA for subsequent transformation into E. coli, HEK293 cells were infected with the GFP-and RFP-positive recombinants for 2 h and then harvested. Whole cellular DNA was isolated from Figure 1 (a) Schematic strategy of cloning MGH1 genome into a BAC vector. MGH1 is a strain F-derived HSV-1 mutant that possesses deletions in both copies of the g 1 34.5 gene and a lacZ insertion at the U L 39 locus. A U L 39-targeting BAC plasmid, pRBAC-D6GpA-FL, was constructed so that it contains two homology arms that can recombine with the viral genome upstream and downstream of the lacZ insertion within the U L 39 locus. The construct also has (1) a set of two recombination sequences, loxP and FRT sites, flanking the BAC backbone, (2) an EGFP expression cassette which is inserted in-frame downstream of the truncated U L 39 coding sequence and (3) an RFP expression cassette within the BAC backbone. The linearized pRBAC-D6GpA-FL DNA and intact MGH1 virion DNA were co-transfected into Vero cells, and recombinant virus that carries the BAC sequence (MGH1-BAC) was isolated. (b) Schematic outline of the HSVQuik system. The transgene cassette of interest (X) is first cloned into a pTransfer shuttle plasmid and the resulting plasmid (pTransfer-X) is electroporated together with an FLP-expressing helper plasmid into bacteria carrying fHsvQuik-1 BAC plasmid. Co-integrants of the pTransfer-X and fHsvQuik-1 fused at the FRT sites (fHsvQ1-X) can be readily obtained by selection with Cm and Amp at 431C. The fHsvQ1-X has the transgene cassette inserted at the U L 39 locus and two unidirectional loxP sites are now flanking all the procaryotic plasmid backbones as well as the RFP marker gene. Upon co-transfection of the fHsvQ1-X and a Cre-expressing helper plasmid into Vero cells, the procaryotic plasmid backbones, together with the RFP expression cassette, can be excised through Cre-mediated site-specific recombination. As a result, recombinant HSV vectors with the transgene cassette (rHsvQ1-X) can be rescued. Figure 1b ).
Development and characterization of the HSVQuik system
The schematic diagram for the HSVQuik system is shown in Figure 1b . The pTransfer plasmid is an R6Kg-ori containing, replication conditional plasmid with a multiple cloning site (MCS) flanked by a loxP site and an FRT site. First, one or multiple transgene cassettes of interest were inserted into the MCS of the pTransfer by standard ligation.
The transgene cassettes together with the entire shuttle plasmid backbone can be inserted into the FRT site of the fHsvQuik-1 BAC plasmid through Flp-mediated sitespecific recombination in bacteria. (A similar plasmid fusion strategy using Cre recombinase has been described previously. 15, 16 ) Briefly, the pTransfer plasmid with transgene cassettes was co-electroporated with an Flp-expressing helper plasmid (pFTP-T) into bacteria carrying fHsvQuik-1 DNA and clones resistant to both Cm and ampicillin (Amp) were selected at 431C. At this restrictive temperature, the pFTP-T does not replicate and, therefore, neither does its dependent plasmid pTransfer. The sequence of pTransfer (Amp resistant) can be maintained only if it is inserted at the FRT site of the fHsvQuik-1. Indeed, with this method, approximately 80% of Cm-and Amp-resistant clones typically contain correct co-integrants (data not shown). The entire procedure including Flp-mediated plasmid insertion, clone verification and plasmid Maxiprep, typically takes 5 days even when multiple constructions are made at a time. Figure 2a is a representative gel picture showing the HindIII restriction patterns of fHsvQuik-1 and its derived HSV BAC co-integrants (fHsvQ1, fHsvQ1-CMVLuc, fHsvQ1-IE2-Luc, fHsvQ1-TK-Luc and fHsvQ1-ICP6-Luc). In the lanes for these five co-integrants, the 18.5-kb band observed with fHsvQuik-1 was missing and 2-3 new bands at the expected sizes (indicated with arrows) were confirmed.
In order to rescue recombinant vectors, the cointegrated HSV BAC DNA was co-transfected with a Cre-expressing helper plasmid (pc-nCre) into Vero cells. As a result, the procaryotic plasmid backbone sequences, which were flanked with two unidirectional loxP sites, were excised from the co-integrated plasmid (Figures 1b and 3a ) and the progeny HSV recombinants carrying the transgene cassettes of interest were rescued. As shown in Figures 3b and c, recombinant viruses devoid of unwanted plasmid sequences were easily identified by the lack of RFP expression in infected Vero cells. Typically 99% of the rescued viruses were free of procaryotic plasmid backbone, and therefore, such recombinants can be readily isolated either through plaque purification or serial dilution.
The genetic integrity of some of the plasmid constructs and vector genomes generated in this study was examined by PCR and Southern blotting analyses. As shown in Figure 4 , viral lysate samples obtained from RFP-negative plaques (lanes 5-8) were all confirmed Rapid method to generate oncolytic HSV vectors K Terada et al negative for the presence of RFP coding as well as pTransfer backbone sequences. These samples were also positive for the primer sets of both firefly luciferase (Luc) coding and ICP6-Luc junction sequences, confirming correct and complete Cre-mediated excisions. On the contrary, DNA sample obtained from a plaque containing a small number of RFP positive cells (lane 4) was positive for all four primer sets, concluding that it was contaminated with unresolved co-integrant DNA. GFPpositive and RFP-negative recombinant vectors were further amplified in Vero cells and virion DNA was prepared and subjected to Southern blotting analysis. Figure 5 represents the blot data using the BAC backbone and 3 0 portion of ICP6 coding (ICP6-3 0 ) sequences as probes, respectively. These results confirm that vector genomes rescued by Cre-mediated excision (e.g., rHsvQ1, rHsvQ1-Luc-b and rHsvQ1-CMV-Luc-b) were free from BAC sequences and had correct genetic structures around the recombination sites.
In order to verify whether the MGH1 genome was cloned intact as fHsvQuik-1, rHsvQ1 (an HsvQuikderived vector without any insert) was compared with its parental MGH1. As shown in Figure 6a , one-step growth curve experiments revealed that these two viruses possess similar growth profiles over time in Vero cells. Furthermore, cytotoxicity assays revealed that MGH1 and rHsvQ1 showed similar degrees of cytotoxicity against Gli36DEGFR, U343 and MRC9 cells ( Figure  6b ). Neurovirulence of these two viruses were evaluated by injecting them into the brain of BALB/c mice. All mice injected with up to 1 Â 10 7 PFU (maximum dose achieved) of either MGH1 or rHsvQ1 survived at least for a month without showing any clinical symptoms (n ¼ 5).
In order to characterize various viral promoters in the context of replication-conditional HSV vectors, five firefly luciferase-expressing recombinants (rHsvQ1-ICP6-Luc, -IE4/5-Luc, -IE2-Luc, -TK-Luc and -CMVLuc) were constructed using the HSVQuik method. Gli36DEGFR cells were infected with these vectors and luciferase activity was determined at five different time points (2, 5, 10, 15 and 25 h after infection). As shown in Figure 7 , the HSV IE4/5 and ICP 6 promoters demonstrated the highest luciferase activity.
In vivo screening of oncolytic HSV vectors expressing immunomodulators using syngeneic mouse glioma models KR158B glioma cells, derived from spontaneous glioma formed in Trp53/Nf1 double mutant mice, 17 and 4T1 murine breast cancer cells were retrovirally transduced to express firefly luciferase. The resulting cell lines, designated as KR158B-Luc and 4T1-Luc, were confirmed to form luciferase-labeled tumors when implanted into the brains of C57BL/6 and BALB/c mice, respectively. The growth of these luciferase-labeled tumors was successfully visualized by the increase of the luciferase activity in the animals (Figure 8a ). Oncolytic HSV vectors expressing murine IL4, CD40 ligand (CD40L) and 6CK (secondary lymphoid tissue chemokine or SLC) under the control of the IE4/5 promoter were constructed using the HSVQuik method. Antitumor efficacy of these three vectors along with rHsvQ1 was evaluated using the two luciferase-labeled mouse brain tumor models. First, C57BL/6 mice with KR158B-Luc gliomas were thus treated with stereotactic inoculations of saline, rHsvQ1, rHsvQ1-mIL4, -mCD40L and -m6CK. As shown in Figure 8b , luciferase activity detected from saline-treated animals increased very rapidly (B60-fold increase in 10 days), whereas the increase of luciferase activity detected from rHsvQ1-treated animals retarded considerably (B30-fold increase in 10 days). The growth retardation of the tumors mediated by oncolytic HSV was further enhanced with the expression of IL4, CD40L and 6CK. We then tested these vectors on BALB/c mice bearing 4T1-Luc tumors in the brain (metastatic brain tumor model). The expression of IL4, CD40L and 6CK was confirmed to enhance the HSV-mediated antitumor effects with the metastatic brain tumor model as well (Figure 8c ).
Discussion
Oncolytic HSV vectors are emerging as a promising therapeutic approach for various types of cancer. Major advantages of this vector system include its broad host range of infectivity and replication, its potent anticancer vaccination effects, its large transgene capacity and its clinical safety including the availability of antiherpetic drugs as a safeguard. However, genetic manipulations of the HSV genome and construction of new recombinant HSV vectors by conventional means (homologous recombinations in mammalian cells) can often be a complicated and lengthy process. Previously, we and Rapid method to generate oncolytic HSV vectors K Terada et al others reported the cloning of the entire HSV-1 genome as a BAC, which allowed for stable maintenance as well as versatile genetic modifications of the highly repetitive HSV genomic sequences in bacteria and spontaneous rescue of recombinant viruses upon transfection of the HSV-BAC DNA into mammalian cells. 15, [18] [19] [20] [21] In order to facilitate the process of engineering oncolytic HSV vectors, particularly for introducing various therapeutic transgenes into a defined oncolytic HSV vector backbone (e.g., U L 39-and g 1 34.5-double mutant), we devised a novel BAC-based methodology called the HSVQuik system. This system consists of two components, an HSV-BAC carrying the entire MGH1 9 genome (fHsvQuik-1) and a replication-conditional shuttle plasmid (pTransfer) (Figure 2b) . We designed the fHsvQuik-1 to have the BAC sequences at the deleted U L 39 locus flanked by an FRT site and a loxP site, so that the BAC sequences can be efficiently replaced with virtually any DNA sequences of interest through sequential usages of two site-specific recombinases, Flp and Cre. The Flp-mediated insertion of a pTransferderived shuttle plasmid into the fHsvQuik-1 BAC is the initial step and it works very efficiently (B80%) in bacteria. This entire procedure including Mini-preparation, restriction enzyme analyses and Maxi-preparation of the resulting co-integrants typically takes 4-5 days. The verified co-integrants can serve as stable precursors of recombinant vectors and be maintained indefinitely in bacteria. The following Cre-mediated excision of the procaryotic sequences can be achieved by co-transfecting the BAC-pTransfer co-integrant and the Cre-expressing plasmid into Vero cells. Progeny recombinant viruses can be harvested in 2 days and typically 99% of them are correctly released from the BAC sequences (Figures 3b  and 4b ). The presence of the RFP expression cassette in the BAC backbone facilitates excluding vectors carrying the BAC sequences (typically takes 3 days). Taken together, the HSVQuik system allows generation and isolation of multiple oncolytic vectors within 10 days. The current HSVQuik vector can carry transgene cassettes up to 10 kb in size, but this size limit can be increased further by deleting nonessential sequences of the HSV genome. In fact, we have recently reported two papers in which the HSVQuik system was successfully utilized to generate novel oncolytic HSV vectors. 22, 23 In vivo bioluminescent imaging has become a powerful means to evaluate and monitor tumor growth/clearance in response to various anticancer therapeutics in small animal models. [24] [25] [26] This new methodology is particularly useful when tumors are located deep inside the body such as in brain tumor, lung cancer and liver cancer models, where the assessment of tumor load is difficult without killing the animals. Among the several luciferase genes that are available, firefly luciferase is particularly suitable as a photon-producing marker to label cancer cells because of the following characteristics: (1) the enzyme is a single-subunit enzyme and its enzymatic activity does not require post-translational modifications; (2) its specific substrate, D-luciferin, is relatively inexpensive and commercially available from several suppliers; (3) the photon-generating reaction requires ATP, Mg 2+ and oxygen as cofactors and therefore Rapid method to generate oncolytic HSV vectors K Terada et al bioluminescence signals can be generated only from metabolically active cancer cells; and (4) a yellow-green light with an emission peak at E560 nm, generated by this enzyme, can transmit through deeper tissues compared to Renilla and bacterial luciferases. 26, 27 We thus developed two cancer cell lines (KR158B-Luc and 4T1-Luc) genetically labeled with firefly luciferase expression and successfully established syngeneic primary and metastatic mouse brain tumor models, respectively. Using these two models, we tested a series of oncolytic HSV vectors expressing various immunomodulator genes. As expected, vectors expressing IL4, CD40L or 6CK were confirmed to slow down the speed of tumor growth in immunocompetent mouse models. Although monitoring tumor growth alone does not allow for the understanding of mechanisms of action, the luciferase-labeled syngenic brain tumor models would be a valuable resource to efficiently identify candidate therapeutic immunomodulators that enhance anticancer efficacy of oncolytic HSV vectors.
In conclusion, we have developed a novel methodology that allows for the generation of oncolytic HSV vectors with virtually any transgene of interest within 10 
Materials and methods
Cells and viruses
Vero cells, HEK293 cells, normal primary human fibroblasts (MRC9), murine breast cancer cells (4T1) and human glioma cell lines (U87 and U343) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). A murine glioma cell line (KR158B), derived from spontaneous gliomas formed in Trp53/Nf1 double-mutant mice, was kindly provided by Dr Tyler Jacks at Massachusetts Institute of Technology. 17 These cells were cultured in Dulbecco's modified minimal essential medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin at 371C in 5% (v/v) CO 2 . Human glioma cell lines that express a truncated mutant form of EGFR (Gli36DEGFR 28 and U87DEGFR 29 ) were maintained and propagated in the presence of 0.5 mg/ml puromycin and 400 mg/ml G418, respectively. Firefly luciferase-expressing 4T1 cells (4T1-Luc) and KR158B cells (KR158B-Luc) were established by stable transduction with a retrovirus vector pRERH-Fluc (Terada and Saeki, unpublished material) and cultured in the presence of 200 mg/ml hygromycin B.
MGH1 is an HSV-1 mutant that possesses deletions in both copies of the g 1 34.5 gene and an in-frame E. coli lacZ insertion inactivating the U L 39 (ICP6) gene (Figure 1a ). 9 All of the HSV mutants and vectors used in this study were propagated and titered in Vero cells. Frozen stocks of the vectors were maintained at À801C until use.
Generation of fHsvQuik-1
The structural diagram of the U L 39-targeting BAC plasmid, pRBAC-D6GpA-FL, is shown in Figure 1a . This construct was derived from the pBeloBAC11 (Invitrogen, Carlsbad, CA, USA) and contains the F plasmid origin of DNA replication (F ori) as well as the Cm resistance gene (Cm r ) as a procaryotic selection marker. The DsRed1 (red fluorescent protein, RFP) expression cassette (CMV promoter-DsRed1-SV40 polyA) obtained from the pDsRed1-N1 (Clontech, Palo Alto, CA, USA) was inserted within the BAC backbone between the F ori and the Cm r . This RFP-containing BAC backbone was flanked by an FRT site followed by the ICP6 5 0 homologous recombination sequence (HRS) (nucleotides 86 411-86 980 of the HSV-1 genome) at one end and a loxP site with the ICP6 3 0 HRS (nucleotides 87 745-88 655 of the HSV-1 genome) at the other. The EGFP coding sequence (Clontech) with a PGK polyA signal (derived from pBV-IRES-lacZ-pA 30 ) was placed in-frame down- Viral genomic DNA was isolated from MGH1 virions. The viral particles were first treated with RNase A and DNase I for 3 h at 371C and digested with proteinase K overnight at 371C in the presence of 10 mM EDTA and 1% SDS. The sample was then extracted twice with phenol/ chloroform and subjected to ethanol precipitation. The precipitated DNA was resuspended in TE buffer. The linearized pRBAC-D6GpA-FL DNA was co-transfected with MGH1 viral DNA into Vero cells at various molar ratios using LipofectAMINE (Invitrogen). Viral progeny was harvested 3 days following transfection when cytopathic effects were evident. This progeny was released from cells through three cycles of freeze/ thawing, and it was then plated onto a monolayer of Vero cells for plaque purification. After overlayering the monolayer with 0.75% agarose, the plates were incubated for 5-7 days at 371C in a 5% CO 2 atmosphere. Plaques expressing both GFP and RFP were selected as potential recombinants under a fluorescence microscope. These isolates were amplified once in Vero cells and further inoculated onto HEK293 cells. Whole cellular DNA was isolated from the infected cells 2 h after infection and electroporated into ElectroMax DH10B E. coli cells (Invitrogen), which were then plated onto LB agar containing Cm (15 mg/ml). BAC plasmid DNA was prepared from the resulting bacterial colonies and verified by restriction enzyme digestion followed by agarose gel electrophoresis. One of the clones that appeared to contain the intact MGH1 genome was designated as fHsvQuik-1 (Figure 1b) .
Plasmid construction
The replication-conditional shuttle plasmid pTransfer (Figure 1b) was constructed from the ploxP-A 15 as follows. The 261-bp NcoI-SphI fragment of the ploxP-A was removed and the unique NotI site of the resulting plasmid was disrupted. The pTransfer and its derivatives carry the R6Kg-ori 31, 32 and therefore require the P protein for their replication. The Flp recombinase-expressing helper plasmid pFTP-T was constructed by assembling components from the pFT-A (tetR and Ptet; for tetracycline-inducible Flp expression), pFTA (Flp recombinase), pPIR-A (pir gene; to supply the P protein to support the replication of co-introduced pTransfer plasmid or its derivatives) 31 and pMBO96 (pSC101 ts ori and Tc r ; to make the plasmid temperature sensitive and tetracycline resistant). 33 The mammalian Cre expression vector pc-nCre was constructed by inserting the 1.1-kb EcoRI-SalI DNA fragment encoding the Cre recombinase with SV40 nuclear localized signal derived from the pBabe-Cre 34 between the EcoRI and XhoI sites of the pcDNA3.1/Zeo (+) vector (Invitrogen). The construction details and sequence information on the p-Transfer derivatives carrying firefly luciferase expression cassettes or immunomodulator expression cassettes is available upon request.
Flp-mediated site-specific recombination in E. coli Electrocompetent bacteria cells containing the fHsvQuik-1 BAC plasmid were prepared as described previously 15 and were electroporated with a DNA mixture containing both pTransfer-derived shuttle plasmid and pFTP-T helper plasmid (10-50 ng each) using a Bio-Rad Gene Pulser (Bio-Rad, Hercules, CA, USA) set to 25 mF, 1.8 kV and 200 O. The cells were then transferred into 1 ml of SOC medium containing heat-inactivated chlorotetracycline (20 mg/ml) to induce Flp expression and incubated for 3-4 h at 301C (permissive temperature for the helper pFTP-T and, therefore, also for the insertional shuttle plasmid pTransfer) with rigorous shaking. The resulting culture was then plated onto LB agar plates containing Cm (15 mg/ml) and Amp (50 mg/ml) and incubated overnight at 431C (restrictive temperature for pFTP-T). The resulting colonies were propagated overnight at 371C in LB medium containing Cm and Amp and the plasmid mini-prep samples were subjected to restriction enzyme digestion and Southern blotting analyses. The identified correct clones were then propagated in 250 ml LB, and BAC DNA was extracted using the Qiagen Plasmid Maxi Kit (Qiagen, Valencia, CA, USA).
Rescue of recombinant HSV vectors using Cremediated site-specific excision in Vero cells
Vero cells (5-7 Â 10 5 cells per P60 culture plate) were plated. On the following day, 2 mg of the BAC DNA and 0.5 mg of the pc-nCre DNA were co-transfected into the Vero cells using LipofectAMINE (15 ml). Viral progeny was harvested 3 days after transfection. This progeny was plated onto a monolayer of Vero cells. After overlayering the monolayer with 0.75% agarose, the plates were incubated for 5-7 days at 371C. Plaques expressing GFP but not RFP were selected under a fluorescence microscope. The plaque-purified recombinant vectors were propagated in Vero cells.
PCR analysis
PCR-amplified fragments were obtained using viral genomic DNA or plasmid DNA as template and the oligonucleotide primers listed bellow. Taq DNA polymerase (Qiagen) was used to amplify the region of interest with 40 cycles (951C, 30 s, 551C, 30 s, 721C, 60 s). Viral genomic DNA was prepared from crude viral lysate harvested at 60-72 h post-infection. Briefly, crude viral lysate was diluted fivefold with TE buffer, boiled for 30 min, and centrifuged to remove insoluble fractions. The supernatant was further diluted with water (typically 10-fold) and directly used as template for PCR amplification. The primers used in this study were as follows: RFP 5 0 -aaggagttcatgcgcttcaa (P1) and 5 0 -ctcggtgcgctcgtactgct (P2); pTransfer backbone 5 0 -caggtt gaactgcggatctt (P3) and 5 0 -tgcgcaaactattaactggc (P4); Luciferase 5 0 -ttgtgccagagtccttcgat (P5) and 5 0 -tcagagactt caggcggtca (P6); and ICP6-Luciferase junction 5 0 -cgaag taccgaaaggtctta (P7) and 5 0 -tcgcgaagcctttccgtcag (P8).
Southern blotting analysis
Virion DNA was isolated from HSV vectors as described above. One microgram of each BAC DNA and virion DNA was digested with HindIII, electrophoresed on a 0.6% agarose gel, and transferred to a nylon membrane (Hybond N+; Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA). Southern analyses were performed using the AlkPhos Direct DNA labeling and detection kit 
Bioluminescence imaging
Imaging of luciferase-expressing tumors in mice was performed as reported previously. 35 Mice were anesthetized (15 mg/kg ketamine+3 mg/kg xylazine, intraperitoneal injection), injected intraperitoneally with D-luciferin (100 mg/kg weight) and bioluminescence read-outs were obtained with a cryogenically cooled, super-sensitive charge-coupled device camera system (Roper Scientific, Trenton, NJ, USA). After data acquisition, postprocessing and visualization were performed with CMIR-image software. 35 Regions of interest were defined by an automatic intensity contour procedure to identify bioluminescence signals with intensities significantly greater than background. The mean, standard deviation and sum of the photon counts in these regions were then calculated.
